Abstract: Products of a general formula (I) and their use in the manufacture of medicines useful for the treatment of neurodegenerative diseases such as Alzheimer's disease or, in general, any disease or pathology produced by alterations of biological functions that can be treated or therapeutically modified by these products.

Abstract: The present invention generally relates to a method for the identification of compounds for the treatment of neurodegenerative diseases. Said method is based on a cell model for neurodegeneration useful for the identification of potentially useful compounds for the treatment or the prevention of a neurodegenerative disease associated with deficient expression of the DDIT3 gene, also known as CHOP.

Abstract: The present invention relates to a new compound derived from ruthenium, of formula (I), known as pentaamin ruthenium [3-(2-phenanthren-9-yl-vinyl)pyridine] complex, as well as the use thereof as an electrochemical indicator of hybridization in a method for the detection of hybridization between nucleic acid sequences, for the quantification of said sequences, as well as the detection of the presence of a mismatched base and the position thereof within a nucleic acid sequence.

Abstract: The Snail transcription factor has been identified as a repressor of the expression of E-cadherin. The expression of Snail induces invasive and metastatic capacity in tumour cells. This invention presents: a new target protein, Snail, for the identification of new antitumoral compounds and a new diagnostic tumour marker, indicative of tissue invasion and metastatic capacity.

Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

Abstract: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.

Abstract: Compounds of general formula (I): where A, E, G, X, Y and the bond - - - take various meanings are of use in the preparation of a pharmaceutical formulation, for example in the treatment of a disease in which GSK-3 is involved, including Alzheimer's disease or the non-dependent insulin diabetes mellitus, or hyperproliferative disease such as cancer, displasias or metaplasias of tissue, psoriasis, arteriosclerosis or restenosis.

Abstract: Described is a method for cancer detection, progression analysis and malign tumor prognosis based on the study of metabolic markers of the cell. The method consists in using the study of the protein expression of the bioenergetic function of the mitochondrion, such as the beta-catalytic subunit of the H-ATP synthase, in relation to structural proteins and mitochondrial respiration, such as hsp 60 and cytochrome oxidase subunits I and IV respectively, and said mitochondrial bioenergetic index, (ratio of beta-ATPasa/hsp60; beta-ATPasa/COX I; beta-ATPasa/COX IV) which relates to the cellular protein expression of the glycolytic pathway, such as glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase M, in order to generate the bioenergetic index of the cell.

Abstract: The invention relates to a transgenic non-human animal which can be used as a non-human animal model for studying Alzheimer's disease (AD) and which is characterized in that: it contains a heterologous polynucleotide (transgene) which is inserted in the genome thereof and which comprises the nucleotide sequence of the complete human APP gene together with the regulatory sequences thereof; and it has an endogenous expression pattern similar to that of the hAPP gene in humans. The inventive model can be used to study AD and in the screening of potentially-useful compounds for the prevention and/or treatment of AD.

Abstract: This invention relates to a compound that induces or activates telomerase activity based on the nucleotide sequence of the GSE 24.2 fragment of dyskerin or the protein or peptide sequence encoded by said nucleotide sequence. Another part of the invention relates to vectors that comprise said sequence and cells transformed thereby, and pharmaceutical compositions that contain all these elements. These compositions may be used in the treatment of diseases from the following group: ageing or acceleration of ageing, neurodegenerative diseases and dyskeratosis congenita.

Abstract: An enzymatic process to obtain 4-O-?-D-galactopyranosyl-D-xylose useful in compositions or solutions in the in vivo evaluation of intestinal lactose activity in humans, that comprises the steps of preparing a reaction mixture of D-xylose, a ?-D-galactopyranoside and a reaction medium that comprises water buffered to a pH between 5.0 and 9.0; adding 10 to 1,000 units of ?-D-galactosidase per gram of ?-D-galactopyranoside; subjecting the reaction mixture to a reaction or a temperature between a temperature higher than the freezing point of the reaction mixture and 45° C., for 2 to 48 hours; for the reaction by deactivation of the ?-D-galactosidase; and to isolate and crystallize the fractions that contain 4-O-?-D-galactopyranosyl-D-xylose from a crystallization mixture selected between mixtures of acetone/methanol in a ratio between 5/1 to 20/1 and mixtures of acetone/water in a ratio between 5/1 to 20/1.

Abstract: The present invention provides an oily mixture based on natural bioactive ingredients to be used to prepare an enriched food product that includes salmon oil enriched with EPA and DHA, alpha-tocopherol and supercritical rosemary extract. Optionally, this mixture can contain the microalga Dunaliella salina. The invention also provides a food product enriched with this oily mixture based on natural bioactive ingredients. This enriched food product has great benefits for human health owing to its stable contents of polyunsaturated fatty acids with a ?-3 to ?-6 ratio lower than 5, of alpha-tocopherol, phenolic diterpenes derived from supercritical rosemary extract and, optionally, carotenoids derived from the microalga Dunaliella salina. Finally, the invention also refers to a method to prepare this enriched food product.

Abstract: Antibodies, or antigen-binding fragment thereof, which bind to a CCR7 receptor are capable of selectively killing, impairing migration and/or blocking dissemination of tumour cells expressing a CCR7 receptor. Use of said antibodies for killing or for inducing apoptosis of said tumour is disclosed, thus providing an alternative therapy for treatment of cancer which tumour cells express a CCR7 receptor.

Abstract: The Snail transcription factor has been identified as a repressor of the expression of E-cadherin. The expression of Snail induces invasive and metastatic capacity in tumor cells. This invention presents: a new target protein, Snail, for the identification of new antitumoral compounds and a new diagnostic tumor marker, indicative of tissue invasion and metastatic capacity.

Abstract: The Snail transcription factor has been identified as a repressor of the expression of E-cadherin. The expression of Snail induces invasive and metastatic capacity in tumour cells. This invention presents: a new target protein, Snail, for the identification of new antitumoral compounds and a new diagnostic tumour marker, indicative of tissue invasion and metastatic capacity.

Abstract: A new phosphorylation site of mitogen-activated kinase proteins (MAPK) has been found. Phosphorylated MAPKs in said phosphorylation site can be used as a diagnostic marker of pathologies mediated by MAPKs.

Abstract: A transgenic animal in which GSK-3? protein is over-expressed is useful as a model for neurodegenerative disease.

Abstract: Methods for the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, this invention relates to an adult multipotent cell or a cell population or composition comprising said cell, isolated from non-osteochondral mesenchymal tissue, characterized in that the cell is positive for the following markers: CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 and because it lacks expression of the following markers: CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 and CD133.

Abstract: Provided herein are novel methods and compositions utilizing adipose tissue-derived stromal stem cells for treating fistulae.

Abstract: The Snail transcription factor has been identified as a repressor of the expression of E-cadherin. The expression of Snail induces invasive and metastatic capacity in tumor cells. This invention presents: a new target protein, Snail, for the identification of new antitumoral compounds and a new diagnostic tumor marker, indicative of tissue invasion and metastatic capacity.